Margin expansion from biologics shift
The thesis presented was that Stevanato's revenue mix is shifting towards higher-margin, pre-sterilized 'High-Value Solutions' for biologics, driving significant EBITDA margin expansion without needing cost cuts.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.